Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
indiana blog main
indiana top stories
14
×
life sciences
14
×
national blog main
boston blog main
raleigh-durham blog main
raleigh-durham top stories
biotech
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
clinical trials
eli lilly
amgen
cancer
novartis
teva pharmaceutical
crispr
drugs
ipo
migraine
biogen
bristol-myers squibb
What
new
14
×
drug
bio
fda
roundup
approval
migraine
won
cancer
class
companies
drugs
ipo
medicines
approved
crispr
decades
developed
eli
genetic
group
isn’t
known
life
lilly
medicine
million
oks
pain
pharmaceutical
remains
science
second
starts
testing
therapeutics
wave
activity
acute
addresses
Language
unset
Current search:
new
×
" life sciences "
×
" indiana top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?